Author

Shih-Yuan Lee

Institutions: Université Paris-Sud, Institute of Cancer Research, National and Kapodistrian University of Athens, Aristotle University of Thessaloniki, Institut Gustave Roussy, Université Paris Descartes, Takeda (Japan), University of Glasgow

Observed institutions: Université Paris-Sud, Institute of Cancer Research, National and Kapodistrian University of Athens, Aristotle University of Thessaloniki, Institut Gustave Roussy, Université Paris Descartes, Takeda (Japan), University of Glasgow

OpenAlex ID: A5063545142

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5

2015 · Karim Fizazi, Robert Jones, et al. · Journal of Clinical Oncology · 157

Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen

2014 · Maha Hussain, Paul G. Corn, et al. · Clinical Cancer Research · 35

Works count: 2

Citation count: 192

H-index: 2

I10-index: 2